Alzamend Neuro annual meeting: all proposals pass, including reverse stock split up to 1:10

Alzamend Neuro, Inc.

All seven director nominees elected, including William B. Horne, Milton C. Ault III, Stephan Jackman, Henry C. Nisser, Mark Gustafson, Lynne F. McGrath, Jeffrey Oram.
Shareholders approved reverse stock split (Proposal 6): ratio 1:2 to 1:10, board discretion, before April 16, 2027. Vote: 1,150,722 for, 445,185 against.
Ratification of Haskell & White LLP as independent auditor (Proposal 2): 1,454,276 for, 114,748 against, no broker non-votes.
Advisory vote on executive compensation (Proposal 3) passed: 276,241 for, 124,274 against, with 1,185,412 broker non-votes.
2025 Stock Incentive Plan (Proposal 4) and equity issuance approval (Proposal 5) also passed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.